These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21458656)

  • 1. Recombinant allergens: what does the future hold?
    Valenta R; Niespodziana K; Focke-Tejkl M; Marth K; Huber H; Neubauer A; Niederberger V
    J Allergy Clin Immunol; 2011 Apr; 127(4):860-4. PubMed ID: 21458656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens.
    Valenta R; Linhart B; Swoboda I; Niederberger V
    Allergy; 2011 Jun; 66(6):775-83. PubMed ID: 21352238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant allergens for immunotherapy.
    Valenta R; Niederberger V
    J Allergy Clin Immunol; 2007 Apr; 119(4):826-30. PubMed ID: 17335886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future.
    Valenta R; Campana R; Focke-Tejkl M; Niederberger V
    J Allergy Clin Immunol; 2016 Feb; 137(2):351-7. PubMed ID: 26853127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.
    Linhart B; Valenta R
    Vaccine; 2012 Jun; 30(29):4328-35. PubMed ID: 22100888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity.
    Focke M; Swoboda I; Marth K; Valenta R
    Clin Exp Allergy; 2010 Mar; 40(3):385-97. PubMed ID: 20210812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current state of recombinant allergens for immunotherapy.
    Pauli G; Malling HJ
    Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):575-81. PubMed ID: 20859201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergy diagnosis, allergen repertoires, and their implications for allergen-specific immunotherapy.
    Crameri R
    Immunol Allergy Clin North Am; 2006 May; 26(2):179-89, v. PubMed ID: 16701139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for converting allergens into hypoallergenic vaccine candidates.
    Vrtala S; Focke-Tejkl M; Swoboda I; Kraft D; Valenta R
    Methods; 2004 Mar; 32(3):313-20. PubMed ID: 14962766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant allergy vaccines based on allergen-derived B cell epitopes.
    Valenta R; Campana R; Niederberger V
    Immunol Lett; 2017 Sep; 189():19-26. PubMed ID: 28472641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From allergen structure to new forms of allergen-specific immunotherapy.
    Valenta R; Kraft D
    Curr Opin Immunol; 2002 Dec; 14(6):718-27. PubMed ID: 12413521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6.
    Linhart B; Mothes-Luksch N; Vrtala S; Kneidinger M; Valent P; Valenta R
    Biol Chem; 2008 Jul; 389(7):925-33. PubMed ID: 18627317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future of allergen-specific immunotherapy.
    Akdis CA
    Expert Opin Emerg Drugs; 2005 Feb; 10(1):1-4. PubMed ID: 15757399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?
    Tulaeva I; Kratzer B; Campana R; Curin M; van Hage M; Karsonova A; Riabova K; Karaulov A; Khaitov M; Pickl WF; Valenta R
    Front Immunol; 2020; 11():1368. PubMed ID: 32733455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant allergen immunotherapy: clinical evidence of efficacy--a review.
    Makatsori M; Pfaar O; Lleonart R; Calderon MA
    Curr Allergy Asthma Rep; 2013 Aug; 13(4):371-80. PubMed ID: 23740287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single recombinant and purified major allergens and peptides: How they are made and how they change allergy diagnosis and treatment.
    Curin M; Garib V; Valenta R
    Ann Allergy Asthma Immunol; 2017 Sep; 119(3):201-209. PubMed ID: 28890016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases.
    Edlmayr J; Niespodziana K; Focke-Tejkl M; Linhart B; Valenta R
    Curr Top Microbiol Immunol; 2011; 352():121-40. PubMed ID: 21626347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant hypoallergens for immunotherapy of Parietaria judaica pollen allergy.
    Asturias JA
    Front Biosci (Landmark Ed); 2009 Jan; 14(12):4606-17. PubMed ID: 19273375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant allergens for pollen immunotherapy.
    Wallner M; Pichler U; Ferreira F
    Immunotherapy; 2013 Dec; 5(12):1323-38. PubMed ID: 24283843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotechnology-based allergy diagnosis and vaccination.
    Bhalla PL; Singh MB
    Trends Biotechnol; 2008 Mar; 26(3):153-61. PubMed ID: 18222557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.